Nevertheless, both men receiving CC and testosterone injections reported similar baseline hypogonadal symptoms. In a cross-sectional retrospective age-matched analysis, we have previously demonstrated that men receiving testosterone injections had higher serum testosterone levels compared to those taking CC. As expected, other studies have reported that men receiving CC had an increase in serum levels of testosterone, FSH, and LH. In men who want to preserve fertility, semen analysis may also be done. Doctors usually order regular blood tests to check testosterone, estradiol, red blood cell counts, and other health markers. No matter which treatment is chosen, safety depends on good medical follow-up. This may be done in men who need the strong symptom relief of TRT but also want to protect fertility. The "best" choice depends on individual goals—whether symptom relief, fertility preservation, or long-term balance is most important. Combination therapy is used in special cases and may offer a middle path. Living with low testosterone can be challenging and take a toll on many aspects of your life. This is causing heterogeneity and does not imply that the effect of the study do count for all different subgroups. Fourth, dosage at start of therapy was chosen based on weight, based on expert opinion in 2012. This may have caused an underestimation of the actual prevalence of side effects. Second, because this was not a placebo controlled trial, it is difficult to conclude if clinical improvement is the result of CC therapy. Side effects were reported in 10% of our population and included agitation, hot flushes, nipple tenderness, mood changes, weight gain, visual changes, headache and dizziness. Long‐term effect of clomiphene citrate (CC) therapy on total testosterone (TT). Men aged above 18 years with low (3 or relatively low TT in combination with clear hypogonadal symptoms, wherefore treatment with CC, were included. Relatively low testosterone was defined as testosterone 10 IU/L were classified as hypergonadotropic hypogonadal males.20 Clomiphene citrate is an effective therapy on short and long term, improving both clinical symptoms and biochemical markers of male hypogonadism with few side effects and good safety aspects. Comparisons were made between baseline and posttreatment hormone levels and symptoms. For men experiencing symptomatic hypogonadism or low testosterone, Clomid acts as a Selective Estrogen Receptor Modulator (SERM). Clomiphene citrate 25 mg is frequently used to initiate testosterone therapy in men with low testosterone. This boost in hormones supports the testes in producing more testosterone, aiding in counteracting low testosterone issues. Consistency in timing may help in maintaining steady hormone levels, so individuals are advised to take it at the same time each day. When comparing Clomid and Letrozole for fertility treatments, Letrozole has been shown to be more effective in certain aspects. Some studies suggest that enclomiphene may lead to quicker results in boosting testosterone compared to the mixed isomer compound. This section provides specific details about its comparison with Enclomiphene, side effects, dosage, and more. This local testosterone is critical for sperm production. TRT and Clomid can sometimes be used together when men want to improve low testosterone symptoms while keeping or restoring fertility. These two hormones are critical for sperm production. Two patients had a reversed biochemical effect within the first 3 months of CC treatment. Only 14/35 (32%) of the physician‐initiated TWM patients continued CC therapy after TWM. Fifty‐two patients had a trial without CC therapy (34%), with a median duration of 3 months (range, 1–12). During treatment, 74% of the patients had subjective symptom improvement, with a median duration till improvement of 3 months (range, 1–24). Two hypergonadotropic patients (1%) had a reversed response of TT after start of CC therapy (see section 4.8). In the orchiectomy patient group, 11/41 patients were hypergonadotropic, and 9/11 patients hypergonadotropic hypogonadal orchiectomy patients were biochemical non‐responders. Selective oestrogen receptor modulators (SERMs), such as clomiphene citrate, are thought to primarily function as oestrogen antagonists to the pituitary gland to drive gonadotropin release, which in turn stimulates spermatogenic and steroidogenic testicular function (2). The tolerability of clomiphene therapy has been reported in a systematic review that found the self-reported incidence of side effects, most commonly, mood changes, and breast tenderness, is from 4 to 11%, and there has been no evidence of clinically significant changes in lipid profiles, bone density, haemoglobin, or prostate-specific antigen (5). However, no randomised controlled trials have compared clomiphene to testosterone replacement (5).
